← Back to Search

Ancillary-correlative (biospecimen collection, chart review) for Breast Cancer

N/A
Recruiting
Led By Helen M Moore
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 10 years
Awards & highlights

Summary

This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. By looking at samples and information collected from the same people over time, researchers hope to better understand how cancer changes over time and over the course of medical treatments.

Eligible Conditions
  • Breast Cancer
  • Cancer
  • Esophageal Cancer
  • Esophageal Carcinoma
  • Gastric Cancer
  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Multiple Myeloma
  • Acute Myeloid Leukemia
  • Cutaneous Melanoma
  • Gastroesophageal Junction Adenocarcinoma
  • Lung Cancer
  • Colorectal Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 10 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 10 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of enrolled patients by cancer type and treatment regimen overall
Procure, store and distribute longitudinal biospecimens and associated clinical data
Secondary outcome measures
Cancer Research Data Commons, The Cancer Imaging Archive and database of Genotypes and Phenotypes data contribution
Pan-cancer gene panel tumor next generation sequencing test
Percentage of collected biospecimens that are delivered to the Patient Derived Models Repository
+4 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Ancillary-correlative (biospecimen collection, chart review)Experimental Treatment2 Interventions
Patients undergo collection of tissue and blood samples prior to initiation of treatment, during treatment, post treatment and at disease progression. Patients with hematological malignancies also undergo collection of bone marrow and cerebral spinal fluid at the same time points. Archival blood and tissue, as well as bone marrow of patients with hematological malignancies, is also collected, if available. Patient medical records are reviewed, and data is collected for at least 5 years.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 2
~1720

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,748 Previous Clinical Trials
40,958,401 Total Patients Enrolled
944 Trials studying Breast Cancer
1,544,008 Patients Enrolled for Breast Cancer
Helen M MoorePrincipal InvestigatorNational Cancer Institute (NCI)
~207 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top